Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.625 USD | -1.76% | +7.45% | -16.03% |
03:40pm | CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate | MT |
May. 23 | CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
MarketScreener Editorial Features
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- MarketScreener Editorial Features